Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked
Spyre Therapeutics, Inc. (NASDAQ:SYRE) fell 13% to $94 on August 26, 2026, but the sell-off sharply overreacted to the underlying data.
Spyre Therapeutics Inc. (SYRE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 4,319,496 | $383,484,855 | +15% | 5.76% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 3,840,778 | $340,984,271 | +97% | 6.38% |
| 3. | Driehaus Capital Richard Driehaus | 2,799,166 | $248,509,957 | +1% | 1.44% |
| 4. | Tang Capital Management Kevin C. Tang | 1,892,200 | $167,989,516 | 7.63% | |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,722,300 | $152,905,794 | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.56 | 90,000 | $50,472.00 | 90,000 | 2022-08-25 | Filing | |
| $0.71 | 28,200 | $20,022.00 | 36,200 | 2022-06-08 | Filing | |
| $2.34 | 80,079 | $187,705.18 | 550,540 | 2022-03-16 | Filing | |
| $1.86 | 42,417 | $78,942.28 | 473,461 | 2022-03-15 | Filing | |
| $1.93 | 67,472 | $130,220.96 | 431,044 | 2022-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $90.00 | 400 | $36,000.00 | 2,845 | 2026-09-02 | Filing | |
| $89.38 | 400 | $35,752.00 | 2,845 | 2026-09-01 | Filing | |
| $88.17 | 6,206 | $547,183.02 | 3,245 | 2026-09-01 | Filing | |
| $87.20 | 16,548 | $1,442,985.60 | 9,451 | 2026-09-01 | Filing | |
| $86.40 | 4,845 | $418,608.00 | 25,999 | 2026-09-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,026,187 | $1,156,464,882 | 0.05% | |
| 2. | 6,506,605 | $577,656,391 | 0.01% | |
| 3. | 4,251,996 | $377,492,205 | 3.22% | |
| 4. | 3,448,681 | $306,173,899 | 0.01% | |
| 5. | 3,057,416 | $271,437,392 | 0.01% |
News See All
Spyre Therapeutics Stock (SYRE) Tumbles 14% in After-Hours – Here’s What Spooked Investors
Spyre Therapeutics ($SYRE) fell as much as 14% in after‑hours trading on Tuesday after the company said it will stop developing its rheumatoid arth...
12 Best High Short Interest Stocks With Highest Upside Potential
In this article, we will discuss the 12 Best High Short Interest Stocks With Highest Upside Potential.
10 Small-Cap Stocks That Are On Fire Right Now
In this article, we will discuss the 10 Small-Cap Stocks That Are On Fire Right Now.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
In this article, we discuss the Billionaire Joe Edelman's Stock Picks with Huge Upside Potential.
10 Best 52-Week High US Stocks to Buy
In this article, we will discuss the 10 Best 52-Week High US Stocks to Buy.
10 Stocks With Monster Returns
Ten stocks boasted strong double- to triple-digit gains last week, outperforming a mostly optimistic US market amid US and Iran’s efforts for a peace deal.
10 Stocks With Eye-Popping Gains
Ten stocks kicked off the trading week with double-digit gains, with five notably reaching fresh record highs, thanks to a broader market optimism and positive corporate developments.
Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026
Spyre Therapeutics (NASDAQ:SYRE) is one of the 17 biotechnology stocks with more than 50% upside.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Hedge Fund Resource Center